DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT® cardiovascular outcomes trial with VASCEPA®/VAZKEPA® (icosapent ethyl), as well as abstracts showcasing the mechanistic activity of eicosapentaenoic acid (EPA) that will be presented at the European Society of Cardiology (ESC) Congress in London, United Kingdom, August 30 – September 2, 2024.
Coronary/Structural Heart
Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2024 CIRSE Annual Congress
Presentation to discuss latest developments in future AI applications in interventional radiology, specifically highlighting the early results from the Company’s ongoing proof-of-concept (PoC) human clinical trial
Nanox Receives FDA Clearance for HealthCCSng V2.0, Upgraded Version of Advanced AI Cardiac Solution Empowering Physicians in Assessment of Coronary Artery Calcium
HealthCCSng V2.0 introduces additional ‘zero calcium’ categorization of coronary artery calcium (CAC) and generates a numerical calcium score with corresponding CAC detection category output
AVS Partners with the Jacobs Institute to Expedite Clinical Trials for Coronary and Carotid Indications
August 20, 2024 07:58 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its Pulse Intravascular Lithotripsy platform, today announced it has entered into a strategic agreement with the Jacobs Institute, a nonprofit medical device […]
Heart Failure Society of America Launches Online Repository for Statistical Heart Failure Data and Graphics
WASHINGTON, Aug. 20, 2024 /PRNewswire/ — The Heart Failure Society of America (HFSA) has launched a new online repository called HFStats.org, for statistical heart failure data, in the form of graphics, PowerPoint slides, fact sheets, and more as part of the HF Stats program. Beginning…
Carilion Clinic further expands quality cardiac care access with latest Philips innovations at new regional cardiovascular institute in Virginia, US
August 20, 2024
Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System
BOSTON, Aug. 15, 2024 /PRNewswire/ — Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, today announced the full market release of its VASCADE MVP® XL mid-bore venous closure system. The…
Analytics for Life and CorVista Health Announce the Publication of their Cost Economic Analysis for Non-Invasive Coronary Artery Disease Testing in the Journal of Visualized Experiments
TORONTO & BETHESDA, Md.–(BUSINESS WIRE)–Today, Analytics for Life, a leading innovator in advanced point-of-care diagnostics, and CorVista Health, pioneers in non-invasive cardiac diagnostics, announced a publication of a new comprehensive cost economic analysis of their non-invasive point-of-care test for Coronary Artery Disease (CAD) in the Journal of Visualized Experiments (JoVE). “We […]
Elixir Medical to Present Late-Breaking One-Year Primary Outcomes from the 2,400 Patient INFINITY-SWEDEHEART Clinical Trial at ESC Congress 2024
MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced it will present one-year clinical outcomes from the 2,400 patient INFINITY-SWEDEHEART Randomized Clinical Trial (RCT), a prospective, multi-center, single-blind, clinical trial comparing the drug-eluting DynamX Coronary Bioadaptor System with the contemporary Resolute OnyxTM zotarolimus drug-eluting stent […]
Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
Company to Focus on Targeted Promotion of INPEFA® in Heart Failure While Prioritizing Investment in the Potential Launch of ZYNQUISTA™
